Australian women with an aggressive form of breast cancer now have affordable access to two treatments through the Pharmaceutical Benefits Scheme.
The anti-cancer therapies Perjeta (pertuzumab) and Kadcyla (trastuzumab emtansine) are available to women with advanced HER2-positive breast cancer through the PBS from July 1.
Oncologist Professor Fran Boyle, from Sydney's Mater Hospital, said it had taken almost two years for the therapies to be made widely available.
"We are thrilled that Australian women with advanced HER2-positive breast cancer will finally have the same affordable access to these cancer treatments as women in many other countries," she said.
More than 14,000 Australian women are diagnosed with breast cancer each year, with about 20 per cent of them having HER2-positive breast cancer.
Share
